Effect of Dangfei Liganning capsules on patients with chronic hepatitis B and prediction of network pharmacological mechanism
Objective To observe the clinical efficacy and predict the mechanism of action of Dangfei Liganning capsule in the treatment of chronic hepatitis B(CHB)patients.Methods 98 patients with CHB who were diagnosed and treated in the Third People's Hospital of Kunming from August 2019 to December 2020 were collected,and divided into control group and observation group with 49 cases each according to random number table method.The control group was treated with entecavir,and the observation group was treated with Dangfei Liganning capsule combined with entecavir for 24 weeks.The changes of liver function index,such as total bilirubin(TBIL),alanine aminotransferase(ALT),aspartate aminotransferase(AST),glutamyltransferase(GGT),hepatitis B e antigen(HBeAg)conversion rate,HBV DNA load and liver stiffness measurement(LSM)value were observed before and after treatment between two groups;based on the method of network pharmacology,the theoretical mechanism of the effect of Dangfei Liganning capsule in the treatment of CHB was predicted.Results After treatment,the liver function indexes TBIL,ALT,AST and GGT in the control group were(20.61±10.17)μmol/L,(53.28±17.90)U/L,(49.32±15.24)U/L and(41.97±13.34)U/L,respectively;the clearance rate of HBeAg was 24.49％,the HBV DNA load was(3.34±1.25)log10 copies/mL,and the LSM value was(8.95±1.14)kPa.The liver function indexes TBIL,ALT,AST and GGT in the observation group were(18.75±9.76)μmol/L,(49.74±18.25)U/L,(46.19±17.63)U/L and(39.28±14.11)U/L,respectively;the clearance rate of HBeAg was 30.61％,the HBV DNA load was(2.07±1.18)log10 copies/mL,and the LSM value was(7.43±1.06)kPa.Compared with the control group,the indexes of liver function in the observation group were lower than those in the control group,but the differences were not statistically significant(t=0.924,0.969,0.940,0.970;all P＞0.05).The HBV DNA load and LSM value in the observation group were significantly lower than those in the control group(t=5.172,6.835;all P＜0.05).The screening of Dangfei Liganning capsules obtained 40 active ingredients,which might exert clinical efficacy by acting on targets such as signal transducer and activator of transcription 3(STAT3),JUN,mitogen-activated protein kinase 1(MAPK1)to regulate CHB pathways.Conclusion When Dangfei Liganning capsule combined with entecavir for the treatment of patients with chronic hepatitis B,it could effectively improve patients'liver function and reduce HBV DNA load,and also significantly reduce the LSM value and improve the degree of liver fibrosis.
NETL
NSTL
万方数据
